Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix.
After injury, the wound space is filled with a fibrin/fibronectin clot containing growth factors released by platelets and monocytes. In response to these factors, fibroblasts migrate into the fibrin clot and contribute to the formation of granulation tissue. The functional mechanisms allowing fibroblasts to leave the collagenous matrix of normal connective tissue and invade the provisional matrix of the fibrin clot have not been fully defined. To investigate these mechanisms we established a new in vitro model which simulates specific aspects of early wound healing, that is, the migration of fibroblasts from a three-dimensional collagen matrix into a fibrin clot. This transmigration could be induced by physiological concentrations of platelet releasate or platelet-derived growth factor BB (PDGF-BB) in a concentration-dependent manner. At 24 hours irradiated fibroblasts invaded the fibrin gel almost as well as non-irradiated cells, indicating that transmigration was independent of proliferation. Plasminogen and its activators appear to be necessary for invasion of the fibrin clot since protease inhibitors decreased the amount of migration. These serine proteases, however, were not necessary for exit from the collagen gel as fibroblasts migrated out of the collagen gel onto a surface coated with fibrin fibrils even in the presence of inhibitors. Removal of fibronectin (FN) from either the collagen gel or the fibrin gel markedly decreased the number of migrating cells, suggesting that FN provides a conduit for transmigration. Cell movement in the in vitro model was inhibited by RGD peptide, and by monoclonal antibodies against the subunits of the alpha5 beta1 and alpha v beta3 integrin receptor. Thus, the functional requirements for fibroblast transmigration from collagen-rich to fibrin-rich matrices, such as occurs in early wound healing, have been partially defined using an in vitro paradigm of this important biologic process.
Greiling
D
D
Department of Dermatology, School of Medicine, SUNY at Stony Brook, New York 11794-8165, USA.
Clark
R A
RA
D015703:Antigens, CD / Q000502:physiology; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D003094:Collagen / Q000502:physiology*; D005109:Extracellular Matrix / Q000502:physiology; D005337:Fibrin / Q000502:physiology*; D005347:Fibroblasts / Q000187:drug effects / Q000502:physiology*; D005353:Fibronectins / Q000502:physiology*; D006801:Humans; D039482:Integrin alpha5; D039564:Integrin alphaV; D019012:Integrin beta1 / Q000502:physiology; D008274:Magnesium / Q000494:pharmacology; D008954:Models, Biological; D009842:Oligopeptides / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D019030:Receptors, Vitronectin / Q000502:physiology; D014945:Wound Healing / Q000187:drug effects
D015703:Antigens, CD; D005353:Fibronectins; D039482:Integrin alpha5; D039564:Integrin alphaV; D019012:Integrin beta1; D009842:Oligopeptides; D010982:Platelet-Derived Growth Factor; D011480:Protease Inhibitors; D019030:Receptors, Vitronectin; C047981:arginyl-glycyl-aspartic acid; D005337:Fibrin; D003094:Collagen; D008274:Magnesium